A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI)

Visalli, N; Cavallo, Maria Gisella; Signore, Alberto; Baroni, Marco Giorgio; Buzzetti, Raffaella; Fioriti, Elvira; Mesturino, C; Fiori, Rossana; Lucentini, L; Matteoli, M. C.; Crinò, Antonino; Corbi, Stefania; Spera, S.; Teodonio, C; F, Paci; Amoretti, R.; Pisano, L; Suraci, C; Multari, G; Sulli, N.; Cervoni, M.; Mattia, G. De; Faldetta, Maria R. Cassone; Boscherini, B; Bitti, Maria Luisa Manca; Marietti, G.; Ferrazzoli, Federica; Bizzarri, Carla; Pitocco, Dario; Ghirlanda, Giovanni; Pozzilli, Paolo

doi:10.1002/(sici)1520-7560(199905/06)15:3<181::aid-dmrr31>3.0.co;2-h

Cited by 41 publications

(11 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The active coenzyme forms (nicotinamide adenine dinucleotide NAD and NAD phosphate) are essential for the functions of hundreds of enzymes and normal carbohydrate, lipid and protein metabolism. [103] The effects of nicotinamide supplementation have been studied in several trials focusing on the development[104–107] and progression[108–110] of type 1 diabetes a meta analysis[111] and one small trial in type 2 diabetes. [112]…”

Section: Dietary Supplementmentioning

confidence: 99%

Alternative therapies useful in the management of diabetes: A systematic review

et al. 2011

View full text Add to dashboard Cite

Diabetes mellitus is a metabolic disorder in the endocrine system. This dreadful disease is found in all parts of the world and becoming a serious threat of mankind health. There are lots of chemical agents available to control and to treat diabetic patients, but total recovery from diabetes has not been reported up to this date. In addition to adverse effects, drug treatments are not always satisfactory in maintaining euglycemia and avoiding late stage diabetic complications. Alternative to these synthetic agents, plants provided a potential source of hypoglycemic drugs and are widely used in several traditional systems of medicine to prevent diabetes. Several medicinal plants have been investigated for their beneficial effect in different type of diabetes. Other alternative therapies such as dietary supplements, acupuncture, hydrotherapy, and yoga therapies less likely to have the side effects of conventional approaches for diabetes.

show abstract

Section: Dietary Supplementmentioning

confidence: 99%

Alternative therapies useful in the management of diabetes: A systematic review

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Visaiii et al, 8 < 0.4 U/kg/day for a minimum of 1 month in combination with glycosylated hemoglobin (HbA] C ) within the normal range 16,7 '". However, other authors used a lower limit of insulin requirement to define partial remission; i.e.…”

Section: Referencementioning

confidence: 99%

Factors Influencing Remission Phase in Children with Type 1 Diabetes Mellitus

Büyükgebiz

Ap²,

Böber³

et al. 2001

Journal of Pediatric Endocrinology and Metabolism

View full text Add to dashboard Cite

Type 1 diabetes mellitus (DM) is characterized by selective and progressive autoimmune destruction of ß-cells of the pancreas in genetically susceptible individuals. This autoimmune process takes years before the patient eventually develops clinical DM. Over the course of the disease, some patients regain their ability to secrete endogenous insulin to some extent for a period of few months to years. This partial remission phase has drawn a lot of attention since it offers a window of opportunity to intervene in an attempt to restore pancreatic ß-cell function or to prevent development of the disease in the prediabetic population at risk. Several factors, including age, sex, pubertal status, metabolic findings at the time of presentation, HLA types, presence of diabetes-associated autoantibodies, have been recognized to affect the likelihood of partial or complete remission in children with type 1 DM. Several interventions in patients with new-onset type 1 DM have been tried, including oral nicotinamide and immunomodulatory and immunosuppressive treatments, in an attempt to preserve ß-cell function and to promote or prolong the remission phase, but no conclusive data have been obtained so far. This review summarizes current knowledge on the factors that possibly influence the remission phase in children with type 1 DM.

show abstract

“…The insulin-desensitizing effect has been thought as a potential limitation of nicotinamide treatment in diabetes [5,25,26]. It should be noted that activation of Sirt1 improves insulin sensitivity in rodent models of obesity-induced diabetes [27,28], as well as promotes insulin secretion and β-cell survival in cell culture [17].…”

Section: Discussionmentioning

confidence: 99%

Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice

Fukaya

Tamura

Chiba

et al. 2013

Biochemical and Biophysical Research Communications

View full text Add to dashboard Cite

OBJECTIVE Nicotinamide rescues β-cell damage and diabetes in rodents, but a large-scale clinical trial failed to show the benefit of nicotinamide in the prevention of type 1 diabetes. Recent studies have shown that Sirt1 deacetylase, a putative protector of β-cells, is inhibited by nicotinamide. We investigated the effects of isonicotinamide, which is a derivative of nicotinamide and does not inhibit Sirt1, on streptozotocin (STZ)-induced diabetes in mice. RESEARCH DESIGN AND METHODS Male C57BL/6 mice were administered with three different doses of STZ (65, 75, and 100 mg/kg BW) alone or in combination with subsequent high-fat feeding. The mice were treated with isonicotinamide (250 mg/kg BW/day) or phosphate-buffered saline for 10 days. The effects of isonicotinamide on STZ-induced diabetes were assessed by blood glucose levels, glucose tolerance test, and immunohistochemistry. RESULTS Isonicotinamide effectively prevented hyperglycemia induced by higher doses of STZ (75 and 100 mg/kg BW) alone and low-dose STZ (65 mg/kg BW) followed by 6-week high-fat diet in mice. The protective effects of isonicotinamide were associated with decreased apoptosis of β-cells and reductions in both insulin content and insulin-positive area in the pancreas of STZ-administered mice. In addition, isonicotinamide inhibited STZ-induced apoptosis in cultured isolated islets. CONCLUSIONS These data clearly demonstrate that isonicotinamide exerts anti-diabetogenic effects by preventing β-cell damage after STZ administration. These findings warrant further investigations on the protective effects of isonicotinamide and related compounds against β-cell damage in diabetes.

show abstract

A multi-centre randomized trial of two different doses of nicotinamide in patients with recent-onset Type 1 diabetes (the IMDIAB VI)

Cited by 41 publications

References 57 publications

Alternative therapies useful in the management of diabetes: A systematic review

Alternative therapies useful in the management of diabetes: A systematic review

Factors Influencing Remission Phase in Children with Type 1 Diabetes Mellitus

Protective effects of a nicotinamide derivative, isonicotinamide, against streptozotocin-induced β-cell damage and diabetes in mice

Contact Info

Product

Resources

About